Quanterix Corporation (QTRX) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue:: $40.2 million, a 12% increase year-over-year.

Simoa Revenue:: $23 million, a 36% organic decline.

Spatial Revenue:: $17.2 million, down 9% year-over-year.

Gross Profit:: $17.2 million with a gross margin of 42.8% (non-GAAP gross margin: 45.9%).

Operating Expenses:: $54.5 million, including $15 million related to acquisition and integration costs.

Adjusted EBITDA:: Loss of $11.9 million, compared to a loss of $5.5 million in Q3 2024.

Cash Position:: Ended the quarter with $138 million in cash and equivalents; expects to finish the year with approximately $120 million in cash and no debt.

2Strategic Updates and Business Highlights

Successful integration of Akoya, achieving $67 million of the targeted $85 million in synergies within three months post-acquisition.

Continued investment in R&D, totaling $27 million year-to-date (approximately 30% of revenue), focusing on Alzheimer's diagnostics and new assays.

Early commercial momentum observed from combining Simoa and Spatial technologies, with cross-selling opportunities emerging in oncology and neurology.

Launch of an early access program for Simoa One, aimed at gathering feedback ahead of a broader launch.

3Forward Guidance and Outlook

2025 Revenue Guidance:: Expected to be between $130 million and $135 million, with Simoa revenue projected at $100 million to $105 million.

Gross Margin Guidance:: GAAP gross margin expected between 45% and 47%.

Adjusted Cash Usage:: Anticipated to be between $34 million and $38 million for the full year.

2026 Outlook:: Cash flow breakeven expected, with continued investment in growth initiatives.

4Bad News, Challenges, or Points of Concern

Organic Revenue Decline:: Simoa's consumable revenue declined significantly due to smaller project sizes in the academic sector, attributed to a challenging grant environment.

Market Uncertainty:: Ongoing government shutdown and uneven demand across academic and pharmaceutical markets create uncertainty for Q4 and beyond.

Increased Operating Expenses:: Sequential increase in operating expenses due to integration costs, raising concerns about profitability in the short term.

Competitive Pressures:: Emerging competition in high-sensitivity and multiplex platforms poses a challenge, particularly in the academic and discovery markets.

5Notable Q&A Insights

Consumable Revenue Decline:: Management noted that while order volume remained stable, the size of orders decreased, impacting revenue. They expect project sizes to scale in 2026.

Integration Progress:: The integration of Akoya is ahead of schedule, with a unified leadership team and operational consolidation already in place.

Diagnostics Revenue:: The company anticipates stronger traction in diagnostics in 2026, supported by a positive pricing recommendation for the LucentAD test.

Cross-Selling Opportunities:: Early success in cross-selling between Simoa and Spatial products is being tracked, with positive initial feedback from customers.

Government Shutdown Impact:: The Q4 guidance reflects the potential impact of the government shutdown, with management expressing cautious optimism about a recovery if normalcy resumes. Overall, Quanterix demonstrated resilience in a challenging environment, with strategic initiatives in place to drive future growth despite current headwinds.